培美曲塞联合顺铂治疗晚期卵巢癌的临床研究

目的探讨培美曲塞联合顺铂治疗晚期卵巢癌的临床疗效及安全性。方法 53例晚期卵巢癌患者,给予培美曲塞500 mg/m2,第1天,静脉滴注;同时给予顺铂30 mg/m2,第1~3天,静脉滴注〉2 h,28 d为1个周期,治疗2~4个周期。治疗满2个周期后评价临床疗效、不良反应、生存时间、疾病进展时间,同时进行生活质量评分及KPS评分。结果治疗有效率为49.06%,平均疾病进展时间为8.52个月,平均生存时间为15.01个月。治疗前KPS评分为（64.5±5.0）分,明显低于治疗后（78.2±6.6）分。治疗后功能评分、症状评分、整体生活质量评分较治疗前均有显著改善。结论培美曲塞联合顺铂是治疗晚期卵巢癌的有效治疗方案,不良反应耐受较好。

Clinical study of pemetrexed combined with cisplatin in advanced ovarian cancer

Objective To investigate the clinical efficacy and safety of pemetrexed in combination with cisplatin in the treatment of advanced ovarian cancer.Methods A total of 53 patients with advanced ovarian cancer were treated as follows： pemetrexed 500 mg/m2 d1,intravenous infusion,plus cisplatin 30 mg/m2 d1-d3,intravenous infusion2 h,28 d as a cycle,2 to 4 cycles in all.The clinical efficacy,adverse events,survival time,disease progression time,quality of life score and KPS score were evaluated after two cycles.Results The efficacy rate was 49.06% and the average disease progression time was 8.52 months with an average survival time of 15.01 months.KPS score before treatment（64.5±5.0） was significantly lower than that after treatment（78.2±6.6）.Function scores,symptom scores,and overall quality of life scores were significantly improved after treatment.Conclusion Pemetrexed combined with cisplatin is an effective treatment program for advanced ovarian cancer with better tolerance to adverse events.